Uncategorized
Iontophoretic EGP-437 shows positive early results in treatment of postop ocular inflammation, pain
Iontophoretic EGP-437 showed positive early results in a phase 1b/2a trial evaluating the treatment of ocular inflammation and pain after cataract surgery, EyeGate Pharmaceuticals announced in a press release.The trial included 40 patients who underwent cataract surgery with posterior chamber IOL implantation. Patients were assigned to one of four cohorts and administered iontophoretic EGP-437 at 9 mA-min or 14 mA-min on day 0, day 1 and day 2 or day 0, day 1 and day 4 with the potential for additional treatment on day 7 in all four cohorts.